Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Examine funds that maximize after-tax gains for retirement. This overview focuses on tax efficiency and long-term retirement growth.
27,364 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Fixed notes are more than a loan term. They can be a proactive hedge against vacancy gaps. Learn how investors using ...
As Dyadic gears up to report dyadic (dyai) 2025 earnings, investors should focus on revenue mix, cash runway, and par...
Swsh, a college photo-sharing app, pivots from campus albums to an AI-powered data engine that markets fan content to...
As AI workloads surge, Celestica could play a pivotal role in data-center hardware. This guide breaks down the busine...
In 2026, investors face a choice between a reliable components maker and a bold energy storage innovator. This guide ...
Intel stock looks beaten in the near term, but long-term possibilities remain. This guide breaks down the factors tha...
As velocity financial readies its quarterly release, investors seek clues about growth, profitability, and risk. This...
MicroStrategy unveils a refreshed liquidity framework, lifting cash reserves but leaving questions about its long-ter...
Ethereum is reclaiming the $2,000 zone and shaping a clearer path higher as traders assess the next breakout. The nex...
AI breakthroughs ignite excitement, but investors must separate hype from real value. This guide dives into how to na...
Smart investors look beyond the loud headlines. This guide explains how overlooked stocks soar 2026 by spotting catal...